TerminatedPhase 1NCT00176475
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Principal Investigator
- Roger Strair, MD, PhD, FNP-BCRutgers Cancer Institute of New Jersey
- Intervention
- rituximab(biological)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2008
Study locations (1)
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00176475 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.